Emyria expands MDMA analogue program with UWA
Filed with ASX · · 5 pages · English
We have already identified hits for new disease indications as a result of the screening program this collaboration has enabled. We are excited at the prospect of translating these findings to the clinic, where they can improve quality of life for patients with unmet needs." Highlights: ● Emyria, and partner the University of Western Australia (UWA), have agreed to substantially expand their colla
In the deck
Story so far
Earlier from Emyria
- EMD-RX5 demonstrates excellent safety and bioavailability
- Further positive MDMA analogue screening results received
- Broker Briefing Presentation
- Emyria launches second ultra-pure CBD capsule
- Recruitment commenced for EMD-RX5 Phase 1 Study
Later from Emyria
- Emyria expands drug candidate library inspired by MDMA
- Appendix 4C - Quarterly
- Preclinical studies initiated for MDMA-inspired analogues
- Emyria receives ethics approval for EMD-RX5 Phase 3 trial
- Positive results received for Emyrias MDMA-inspired program
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria